Alexandra Vrabie

Nephrologist, Romania

[Jonathan Zuckerman MD PhD @JZRenalPath]

Sometime the casts have eyelashes. Amyloidogenic variant of light chain cast nephropathy. #renalpath #nephrology #pathtwitter

[Jonathan Zuckerman MD PhD @JZRenalPath]

Exuberant capillary wall spicules in this case of amyloidosis, AHL type. Amyloid spike by EM ('Bart Simpson sign' coined by @JeanHouMD). #renalpath #pathtwitter #nephrology

[Kanishk Gupta, MD @kanishk10246585]

🔬 Spiculated intratubular casts on silver stain, Congo red positivity, and apple-green birefringence point to amyloid cast nephropathy. Paraffin IF confirmed kappa restriction despite negative routine IF.

#RenalPathology #KidneyBiopsy #Amyloidosis #NephPath

[ERA - European Renal Association @ERAkidney]

⏩ Last presentation from #ERA26 LBCT1 session

🎙️@IgAN_JBarratt presenting: Iptacopan achieves near-normal kidney function decline in prespecified IgA nephropathy (IgAN) patient subgroups: APPLAUSE-IgAN final data

🌐Despite current standard of care, up to 50% of patients with IgAN progress to kidney fallure within 10-20 years from diagnosis

🎯 Ideally, to achieve remission we need to achieve proteinuria less than 0.5, or 0. Complement inhibitors might help achieving this, in this case iptacopan (anti factor B man, blocking alternative pathway)

[Daniel Díaz - García @DanielDiazNF]

Atrasentan in IgAN

▫️Atrasentan reduced proteinuria and preserved kidney function after 2.5 years

▫️This effect was present with or without concomitant SGLT2 inhibitor use

🔗https://t.co/NM8JoFvxjS

[Swapnil Hiremath @hswapnil.medsky.social @hswapnil]

short thread - or a story rather on the use of NAC (N-acetyl cysteine) and how it has lead us astray

1/

[ASN Publications @asnpublications]

This #ASNKidney360 study evaluated a large biopsy-confirmed cohort to characterize clinicopathologic features of primary Sjögren’s syndrome with renal involvement and identify predictors of renal recovery and long-term outcomes. Read the article here: https://t.co/3gvpk8s7Mq

[Keith Siau @drkeithsiau]

When to treat high blood pressure: Summary of the 2025 AHA/ACC hypertension guidelines 🚨

https://t.co/OeDnTBjqP5

[Intissar HADDIYA @HaddiyaIntissar]

Can we safely prescribe SGLT2 inhibitors in the case of positive urine dipstick? CANVAS & CREDENCE trials showed that SGLT2i do not increase the risk of UTI. So, in the absence of symptoms, an abnormal dipstick should not lead to withholding SGLT2i.
@AfricanAFRAN @ISNkidneycare

[Eric Topol @EricTopol]

If you've had a kidney stone, you've been advised that the most important thing to prevent another bout is to increase hydration. Now a randomized trial of hydration in over 1600 participants showed no benefit, despite evidence of increase during volume. https://t.co/9ipUGlIsMz

[Hans-Joachim Anders @hjanders_hans]

Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease https://t.co/B65zgGCWMQ

[Andreas Kronbichler @AKronbichler]

Happy to see our review on "challenges" in ANCA-associated vasculitis published in @NatRevRheumatol! A special thanks to the Editorial Team and also @martacasalmoura for leading this initiative! #vasculitis @EUVAS19 @vasculitides

[Vincent Rajkumar @VincentRK]

Just out in the New England Journal of Medicine!

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM https://t.co/7dza0YrFh5

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!

How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here!

MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review

@myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR

[KIReports @KIReports]

Effect of Baseline #Dialysis and #PlasmaExchange on Renal Prognosis in Patients with #ANCA Associated Vasculitis

#VisualAbstract by @NephroSeeker

https://t.co/6O7srTIqmJ

[Mark Perazella @MPerazella]

Also published in the Update on Onco-Nephrology series in Kidney360: Outstanding review on Assessing GFR in patients with cancer!

https://t.co/hVckygUB6K

[Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi]

Patient survival was 91% & kidney survival was 67%. Kidney survival was lower in initially dialysis dependent pts (34% vs 81%). Patients receiving 2nd-line rituximab had better kidney survival compared with those receiving it as 1st-line (73% vs 46%)
https://t.co/M92t66QlWz

[Wladimir Mietek Szpirt @WLASZ]

The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. - Kidney International https://t.co/k4BRQsEpOL

[Rada Miskovic @MiskovicRada]

📌Glucocorticoid withdrawal may be feasible in sustained clinicaly inactive SLE patients maintaining HCQ - results from an open-label, multicentre, non-inferiority, RCT from China https://t.co/IybT1JhNiK

[Laurent ARNAUD @Lupusreference]

✅ FREE access to our NATURE Disease Primer about CAPILLARY LEAK SYNDROME (#Clarkson's + secondary forms) ⬇️ has just been granted by the Editor in Chief, using the following LINK (Valid for 1 month): https://t.co/L67LynVA54

[Laurent ARNAUD @Lupusreference]

✅ Main treatment targets 🎯 for #Lupus #Nephritis at #REICA2024